Application of salvianolic acid B to preparation of medicament for prevention and / or treatment of pulmonary microcirculation disorder or lung injury

A technology of microcirculation disorder and salvianolic acid, applied in the field of medicine, can solve the problems of unclear pulmonary microcirculation disorder and so on

Inactive Publication Date: 2013-12-18
TIANJIN TASLY PHARMA CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is unclear whether salvianolic acid B can improve pulmonary microcirculation disturbance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid B to preparation of medicament for prevention and / or treatment of pulmonary microcirculation disorder or lung injury
  • Application of salvianolic acid B to preparation of medicament for prevention and / or treatment of pulmonary microcirculation disorder or lung injury
  • Application of salvianolic acid B to preparation of medicament for prevention and / or treatment of pulmonary microcirculation disorder or lung injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] tablet

[0077] 【Prescription】Salvianolic Acid B100g Microcrystalline Cellulose 50g Micropowder Silica Gel 3g Magnesium Stearate 1.5g

[0078] [Preparation method] Take raw material and auxiliary materials and pass through 100-mesh sieve respectively; take salvianolic acid B and microcrystalline cellulose, mix well, use 60% ethanol in appropriate amount as binder to make soft material, pass through 20-mesh sieve to make granules, and heat at 60°C Dry, take out, pass through a 30-mesh sieve for granulation, add micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1000 pieces, that is to say.

Embodiment 2

[0080] [Prescription] Salvianolic acid B75g, microcrystalline cellulose 37g, micropowder silica gel 2.3g, magnesium stearate 1.1g

[0081] [Preparation method] Take the raw materials and auxiliary materials and pass through a 100-mesh sieve; take salvianolic acid B, calcium sulfate, and microcrystalline cellulose, mix them evenly, use 60% ethanol in an appropriate amount as a binder to make a soft material, and pass through a 20-mesh sieve to make granules , dried at 60°C, taken out, passed through a 30-mesh sieve for granulation, added appropriate amount of micro-powdered silica gel and magnesium stearate, mixed evenly, pressed into tablets, and made into 1000 pieces.

Embodiment 3

[0083] 【Prescription】Salvianolic Acid B133g Microcrystalline Cellulose 66g Micropowder Silica Gel 4g Magnesium Stearate 2g

[0084] [Preparation method] Take the raw materials and auxiliary materials and pass through a 100-mesh sieve; take salvianolic acid B, calcium sulfate, and microcrystalline cellulose, mix them evenly, use 60% ethanol in an appropriate amount as a binder to make a soft material, and pass through a 20-mesh sieve to make granules , dried at 60°C, taken out, passed through a 30-mesh sieve for granulation, added appropriate amount of micro-powdered silica gel and magnesium stearate, mixed evenly, pressed into tablets, and made into 1000 pieces.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of salvianolic acid B to preparation of medicaments for prevention and / or treatment of pulmonary microcirculation disorder or lung injury. The invention discovers that salvianolic acid B can inhibit expression of pulmonary capilary endothelial cell adhesion molecule-1 and an E-selectin, inhibit adhesion of leucocyte in capillary vessels among alveolars, inhibit leakage of alhumin in capillary vessels among alveolars, inhibit concentrations of tumor necrosis factor alpha and interleukin-8 in blood plasma and alveolar irrigation solution, inhibit expression reduction of lung tissue aquaporin 1 and aquaporin 5, inhibit expression increase of lung tissue metalloprotease 2 and metalloprotease, and mitigate pulmonary edema and lung injury.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of salvianolic acid B in the preparation of medicines for preventing and / or treating pulmonary microcirculation disturbance or lung injury. Background technique [0002] The lung is the first target organ involved in the sepsis process. Acute lung injury (API) and acute respiratory distress syndrome (ARDS) are the main manifestations. Sepsis is an important risk factor for acute respiratory distress syndrome, and ARDS is often the beginning of multiple organ failure in such patients, with high mortality. [0003] Leukocyte-mediated microcirculation injury plays an initiating role in the pathophysiological process of ARDS. In the early stage of ARDS, leukocytes migrate to the lungs under the action of interleukin IL-8 and other chemokines, and under the action of IL-6, etc., the expression of adhesion molecules CD11b / CD18 on the surface of leukocytes is enhanced, and its ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61P11/00A61P7/10
Inventor 韩晶岩林芳刘育英孙凯王传社张淑文
Owner TIANJIN TASLY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap